Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965857 | 0.87 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL8397656 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL3443855 | 0.84 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL3442518 | 0.83 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL8397671 | 0.82 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL3442769 | 0.82 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL30040702 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL11666684 | 0.81 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL10433933 | 0.80 | ALDH1A1 (0.86) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL11751428 | 0.80 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101056863-B | Process for the production of pyrimidine-5-carboxylates | LONZA AG | 2011-04-13 | — | — | CN | disclosed |
| US-20080119651-A1 | one pot reaction without isolating intermediates; reacting oxoalkonate with urea, trimethyl orthoformate in methanol or ethanol to yield a 2-acyl-3-ureidoacrylate, reacting intermediate with 2-hydroxypyrimidine-5-carboxylate in presence of alkali alkoxide, convering it to halo compds. with PO2Cl or SOCl2 | LONZA AG (CH) | 2008-05-22 | — | — | US | disclosed |
| EP-1809609-B1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| CN-101056863-A | Process for the production of pyrimidine-5-carboxylates | LONZA AG (CH) | 2007-10-17 | — | — | CN | disclosed |
| EP-1809609-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048297-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5852028-A | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998038171-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119651-A1 | one pot reaction without isolating intermediates; reacting oxoalkonate with urea, trimethyl orthoformate in methanol or ethanol to yield a 2-acyl-3-ureidoacrylate, reacting intermediate with 2-hydroxypyrimidine-5-carboxylate in presence of alkali alkoxide, convering it to halo compds. with PO2Cl or SOCl2 | HPD, DCTD, POLD1 | ALDH1A1 582/4885SMN1; SMN2 3802/4885LMNA 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.